Targets › ANGPT2
3 programs from 2 companies in 15 trials: 9 Phase 4, 5 Phase 3, 1 Phase 2; Ophthalmology, Oncology; next expected readout Jan 2027.
Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. (UniProt, O15123)
Open in Phaseline: the race on ANGPT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Diabetic Macular Edema | Jan 2027 |
| Roche | Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization … | Sep 2027 |
| Anhui Provincial Hospital | Ivonescimab ANGPT2 inhibitor, anti-angiogenic monoclonal antibody | ANGPT2 | Phase 2 | Esophageal Squamous Cell Carcinoma | Jun 2027 |
Diabetic Macular Edema (2) Esophageal Squamous Cell Carcinoma (1) Neovascular Age-related Macular Degeneration (nAMD) (1) Wet Age-related Macular Degeneration (1) Macular Degeneration Choroidal Neovascularization (1) Macular Degeneration (1) Presumed Ocular Histoplasmosis (1) Polypoidal Choroidal Vasculopathy (1) Macular Degeneration, Age Related (1) Neovascular Age-related Macular Degeneration (1) Polypoidal Choroidal Vasculopathy (PCV) (1) Severe Diabetic Macular Oedema (1)
antibody (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.